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Abstract
Background: Age-related macular degeneration (ARMD) is the leading cause of visual disability in
people over 60 years of age in the developed world. The success of treatment deteriorates with
increased latency of diagnosis. The purpose of this study was to determine the reliability of the
macular mapping test (MMT), and to investigate its potential as a screening tool.
Methods: The study population comprised of 31 healthy eyes of 31 participants. To assess
reliability, four macular mapping test (MMT) measurements were taken in two sessions separated
by one hour by two practitioners, with reversal of order in the second session. MMT readings were
also taken from 17 age-related maculopathy (ARM), and 12 AMD affected eyes.
Results: For the normal cohort, average MMT scores ranged from 85.5 to 100.0 MMT points.
Scores ranged from 79.0 to 99.0 for the ARM group and from 9.0 to 92.0 for the AMD group. MMT
scores were reliable to within ± 7.0 points. The difference between AMD affected eyes and
controls (z = 3.761, p = < 0.001) was significant. The difference between ARM affected eyes and
controls was not significant (z = -0.216, p = 0.829).
Conclusion: The reliability data shows that a change of 14 points or more is required to indicate
a clinically significant change. This value is required for use of the MMT as an outcome measure in
clinical trials. Although there was no difference between MMT scores from ARM affected eyes and
controls, the MMT has the advantage over the Amsler grid in that it uses a letter target, has a
peripheral fixation aid, and it provides a numerical score. This score could be beneficial in office
and home monitoring of AMD progression, as well as an outcome measure in clinical research.
Background
Age-related macular degeneration (AMD) is the advanced
from of age-related macular disease (ARMD) and is the
leading cause of visual disability in patients over the age
of 60 years in the developed World [1]. In the United
States, the demographic right shift is expected to cause an
increase in the number of people affected by this condi-
tion from 1.75 million to almost 3 million by 2020 [2].
Exudative AMD and/or geographic atrophy (GA) can
result in the severe visual loss, and their prevalence in the
US population over 40 years of age has been estimated at
1.47% [95% confidence interval (CI), 1.38% – 1.55%]
[2]. The likelihood of visual deterioration in those with
exudative AMD may be reduced with laser photocoagula-
tion and photodynamic therapy [3-6], but the success rate
deteriorates with increasing latency of diagnosis as lesions
extend towards the foveal avascular zone. Consequently,
early diagnosis is crucial, and at risk patients are often
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scotomas and metamorphopsia [7-9].
The Amsler grid has been used in clinical practice since the
1940s [10] for detecting and monitoring retinal condi-
tions such as age-related macular disease [11-13]. It has
been shown, however, that a report of distortion of the
Amsler grid can come from perceived lines filling-in
across scotomas, or equally from non-scotomatous retinal
impairments; the clinician has no way of knowing which.
Seventy-seven percent of standard and 87 % of threshold
scotomas that are 6° or less in diameter are not detected
by Amsler grid testing [10]. The poor performance of the
Amsler grid may be related to the inability to maintain fix-
ation while testing the peripheral visual field [14], crowd-
ing effects caused by peripheral presentation of multiple
lines [15], inability to assess factors such as quality of
examination performance, and low compliance to per-
form the Amsler grid at home [14]. Despite the shortcom-
ings of this test, the Amsler has been used as a measure of
visual change in a randomised controlled trial (RCT)
investigating the effect of nutritional supplementation in
atrophic AMD [16].
The MMT was designed primarily for quick assessment of
residual vision in patients with maculopathies. However,
the peripheral fixation aid, along with the use of letter tar-
gets may make it a useful tool for monitoring progression
of macular disease. The objective of this study was to
assess reliability (repeatability and reproducibility), and
to assess the effect of ARMD on MMT scores.
The results of this study will allow the use of the MMT as
an outcome measure in clinical research, and may also be
of interest to those who evaluate scotomas for the purpose
of eccentric viewing training.
Methods
Design and setting
This was a reliability study designed to investigate the
reproducibility and repeatability of the MMT. Data was
also collected from ARMD affected eyes to assess the
impact of the disease on MMT score. The study was carried
out in the Neurosciences Research Institute at Aston Uni-
versity, Birmingham, UK, in a clinical research setting.
Subjects
Thirty-one normally sighted participants were recruited
from staff, students, and patients of the Division of
Optometry, Aston University, Birmingham, UK. This
research adhered to the tenets of the Declaration of Hel-
sinki. All participants gave informed consent to take part
in the study, which was approved by the Institutional
Human Ethics Committee. These participants varied in
age from 23 to 77 years (mean ± SD, 50.3 ± 19.0 years).
Visual acuity (VA) ranged from -0.20 to 0.0 (0.00 ± 0.07
logMAR).
Exclusion criteria were: best-corrected logMAR VA of
worse than 0.1 logMAR (VA was measured under standard
testing conditions using a logMAR chart, retro illuminated
to a luminance of 130 cdm-2 [17] and each letter seen was
scored as 0.02 log units, with guessing encouraged); reti-
nal disease detected using a direct ophthalmoscope; glau-
coma; lenticular opacities greater than grade 1 on the
LOCS I grading scale [18]; prescribed medication associ-
ated with changes in retinal function.
The ARMD affected eyes were classified according to the
International Classification and Grading System for Age-
related Maculopathy (ARM) and Age-related Macular
Degeneration (AMD) [19]. ARM refers to large soft drusen
and pigmentary abnormalities of the retinal pigment epi-
thelium (RPE) and the retina, whereas AMD refers to later
stages of the disease such as GA, choroidal neovasculariza-
tion, pigment epithelium detachment, and fibrous scaring
of the macula [19]. Digital fundus photographs were
taken using the Topcon non-mydriatic TRC-NW5S retinal
camera (Topcon House, Bone Lane. Kennet Side, New-
bury, Berkshire RG14 2PX, UK). Eyes were not dilated and
one investigator classified all photographs.
The MMT was carried out on 17 ARM affected eyes of 17
participants aged from 55 to 82 (69.4 ± 7.7 years) and 12
AMD affected eyes of 12 participants aged from 65 to 78
(71.8 ± 4.3 years). VA ranged from -0.08 to 0.2 (0.04 ±
0.09 logMAR) for the ARM group, and from 0.2 to 0.76
(0.50 ± 0.21) for the AMD group. The eyes included did
not have lenticular opacities greater than grade 1 on the
LOCS I grading scale [18], and were not affected by any
other ocular condition. The MMT scores from these
groups were compared with those from 16 normal partic-
ipants aged > 50 years, aged from 51 to 77 (67.1 ± 8.9
years).
Materials
The MMT is a software program used in conjunction with
a desktop or laptop computer, designed specifically to
map visual defects due to macular disease. The test screen
displays a characteristic background pattern throughout
the test, which resembled a 'wagon wheel'. Eight spokes
point inwards, but do not reach the centre of the circular
display area. This pattern provides the patient with suffi-
cient peripheral landmarks to indicate the location of the
centre of the circular display area [20], even if the centre is
not directly visible to the patient (fig. 1).
When loaded for the first time, the program prompts the
user to calibrate the system. It is necessary to measure the
diameter of the wagon wheel, to the check the horizontal/Page 2 of 7
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to maximum contrast and brightness. The diameter of the
wagon wheel on the screen allows the system to suggest a
correct viewing distance, such that the wagon wheel has
the correct angular extent of 18° diameter. The viewing
distance for our system was 76.2 cm.
The targets comprise of the Sloan letters [21] with a
change in the width-to-height ratio from 5 × 5 to 4 × 5 for
better legibility. Serifs are also added to the D to reduce
the probability of confusion with O. Letter sizes vary
according to eccentricity, starting at 5 pixels high, and
increments of 5 pixels to 45 each. Thirty-two standard
locations ensure that the letters do not 'collide' with the
spokes of the wagon wheel. There are an additional four
central locations.
Procedure
All participants were seated comfortably, with their head
supported using a chin rest, and the eye not being tested
occluded. In order to ensure control of direction of gaze,
each participant was asked, 'Do you have a sense of where
the centre of the wagon wheel is?'. All participants
responded positively, and were then instructed to direct
their eye to the centre and to keep it there as still as possi-
ble. Participants with AMD were also advised that the cen-
tre of the wagon wheel may seem to disappear. As the
background illuminance was low (6 lux), and our
Subject view of the MMT resultsFigure 1
Subject view of the MMT results. Black squares indicate letters that were not seen, half-shaded squares indicate those that 
were seen but not correctly identified, and white squares indicate letters that were correctly identified.Page 3 of 7
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one of the LOCS I scale, we were not concerned about
glare, and therefore selected the black letters on a white
background presentation mode. The following explana-
tion of the test was given to every participant; 'Black letters
will appear one at a time anywhere on the white wagon
wheel. It is important that you do not move your eye to try
and look at them. When you see a letter, say the name of
it out loud. If you are not sure what the letter is, have a
guess'.
The same testing room was used for each test with back-
ground lighting switched off. When both eyes matched
the inclusion criteria, the right eye was tested, and when
only one eye was suitable for inclusion, this eye was
tested. The prescription providing best-corrected visual
acuity at the test distance was placed into a trial frame,
with the eye not being tested occluded. Full aperture trial
lenses were used.
When each participant was ready the examiner pressed the
mouse button and a letter appeared in an unpredictable
location in the visual field, remaining visible for 234
msec. The participant told the examiner which letter they
perceived and the examiner entered this response into the
computer for scoring. This prompts display of the next let-
ter, and so on. There are three categories of response; 1)
target not detected, 2) target detected, but not recognized
(including incorrect responses), 3) target correctly recog-
nized. The final score is calculated using the following sys-
tem; target not detected = 0, target detected but not
recognized = 1, target detected = 2. The score is displayed
at the end of the test and the participant is able to view a
'map' of the areas seen and unseen.
Data were collected by two optometrists, HB and LD, dur-
ing two sessions separated by one hour from the same
subjects. A trial run was completed for each subject by HB
in the first session and LD in the second session to encour-
age test familiarity and reduce learning effects. In session
1 the first experimental test was carried out by HB, and the
second by LD, and in session two this order was reversed
The study was designed to assess reproducibility (HB1-
LD1, LD2-HB2), and repeatability (HB1-HB2, LD1-LD2),
Data analysis employed the independent-samples t-test
for comparing ages and the chi-squared test to compare
proportion of males by group. The MMT scores are non-
continuous data, and so we used nonparametric statistical
tests in our analysis. The Mann-Whitney U test was used
to compare MMT scores between groups. When assessing
the effect of ARMD on MMT score, power analysis shows
that the group sizes were sufficient to have an 80% chance
of detecting a difference in means of 5 MMT points at the
5% level of significance using the independent samples t-
test.
Difference in MMT score between HB1 and HB2 compared w th the mean (n = 31 eyes)Figu  2
Difference in MMT score between HB1 and HB2 compared 
with the mean (n = 31 eyes). The mean bias is represented 
by the solid line and the 95 % confidence limits are repre-
sented by the dotted lines.
Difference in MMT score between HB1 and LD1 compared w th the mean (n = 31 eyes)Figu  3
Difference in MMT score between HB1 and LD1 compared 
with the mean (n = 31 eyes). The mean bias is represented 
by the solid line and the 95 % confidence limits are repre-
sented by the dotted lines.
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Reliability
Average MMT scores ranged from 85.5 to 100.0 MMT
points. Reproducibility was determined by comparing
HB1-LD1 and LD2-HB2, and repeatability was deter-
mined by comparing HB1-HB2 and LD1-LD2. The differ-
ences between data sets for two of the comparisons (HB1-
HB2 and HB1-LD1) were normally distributed and these
were used for analysis. See figures 2 to 5 for a graphical
representation of test-retest data of the HB1-HB2, HB1-
LD1, LD1-LD2, and LD2-HB2 comparisons respectively.
Accurate analysis of test-retest data can be achieved using
the coefficient of repeatability [22,23]. This gives the 95%
confidence limits for the amount of difference between
two sets of results. It is calculated as 1.96 multiplied by the
standard deviation of the mean differences between the
two sets of data. The coefficient of repeatability is ± 6.70
for the HB1-HB2 comparison, ± 7.24 for the HB1-LD1
comparison, ± 7.4 for the LD1-LD2 comparison, and ± 4.3
for the LD2-HB2 comparison.
A comparison between HB1 and LD2 has also been made.
The coefficient of repeatability is ± 4.9 and the data is
shown in figure 6.
Effect of ARM
Of the ARM participants, 12 had soft distinct drusen, three
had soft distinct drusen with hyperpigmentation of the
RPE, and two had soft indistinct drusen. The ARM group
and the subset of nomals were matched for age (t = -0.783;
p = 0.439) and gender [χ2 (1) = 0.501, p = 0.579]. Scores
ranged from 85.5 to 100.0 for the subset of normals and
from 79.0 to 99.0 for the ARM group. The mean MMT
score was 94.5 points (94.6 ± 4.8) for the over 50 normal
group and 95.0 points (94.9 ± 4.7) for the ARM group,
and there was no significant difference between the
Difference in Macular Mapping Test (MMT) value between LD1 and LD2, compared with th  mean (N = 30 eyes)Figu  4
Difference in Macular Mapping Test (MMT) value between 
LD1 and LD2, compared with the mean (N = 30 eyes). The 
mean bias is represented by the solid line, and the 95% confi-
dence limits are known by the dashed lines.
Difference in Macular Mapping Test (MMT) value between LD2 and HB2, compared with th  mean (N = 30 eyes)Figu  5
Difference in Macular Mapping Test (MMT) value between 
LD2 and HB2, compared with the mean (N = 30 eyes). The 
mean bias is represented by the solid line, and the 95% confi-
dence limits are known by the dashed lines.
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Difference in Macular Mapping Test (MMT) value between HB1 and LD2, compared with th  mean (N = 30 eyes)Figu  6
Difference in Macular Mapping Test (MMT) value between 
HB1 and LD2, compared with the mean (N = 30 eyes). The 
mean bias is represented by the solid line, and the 95% confi-
dence limits are known by the dashed lines.
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the group sizes were sufficient to have an 80% chance of
detecting a difference in means of 5 MMT points at the 5%
level of significance using the unpaired t-test.
Effect of AMD
All AMD participants had GA, characterised by any
sharply delineated roughly round or oval area of hypopig-
mentation or depigmentation, or apparent absence of the
RPE, in which choroidal vessels were more visible than in
surrounding areas. The size of the lesion was at least 1/8
disc diameters in size. The AMD group and the subset of
normals were matched for age (t = -1.613, p = 0.119) and
gender [χ2 (1) = 0.619, p = 0.821). Scores ranged from 9.0
to 92.0 for the AMD group. The mean MMT score was
62.0 points (61.9 ± 23.8) for the AMD group. The differ-
ence in scores between the over 50 and the AMD group is
statistically significant (z = 3.761, p < 0.001).
Figure 7 shows the effect of age on MMT score for the nor-
mal, ARM and AMD groups.
Discussion
The primary objective of this study was to determine the
reliability of the MMT. The developers of the MMT
assessed its reliability by performing the test twice on 20
eyes. The conditions were made harder between the first
and second run by decreasing the size of the letters by 5
pixels, and 92 % of all tested locations in the participants
behaved within expectation. It was concluded that the test
procedure reflects the functional topography with reason-
able accuracy and reliability [24]. Our reliability data has
been used to determine the decrease in MMT score that is
needed to indicate a clinical change between tests. The
MMT scores are repeatable to within ± 7.0 points, indicat-
ing that the MMT score has to change by more than 14
points for the change to be clinically significant. This
value could be useful if MMT score was being used as an
outcome measure for monitoring progression of ARMD,
or for monitoring the effect of an intervention, e.g. a nutri-
tional supplement.
A limitation of this study design is that the order of the
assessor in each of the two sessions was not randomly
assigned. This would have permitted assessment of the
variance components, assessor, order, and session. How-
ever, a comparison has been made between HB1 and LD2,
and the coefficient of repeatability was smaller than for
other comparisons. This, therefore, does not affect the
reliability conclusions draw.
Comparisons between ARM-affected eyes and age- and
gender-matched controls yielded no significant differ-
ence, although this part of the study was powered to
detect a difference between groups. There was significant
reduction in MMT score between AMD-affected eyes and
age- and gender-matched controls. Our results show that
the MMT is not suitable for screening of ARM.
Conclusion
Although the reliability data indicates variability, the
MMT has the advantage over, for example, the Amsler grid
that it uses a letter target, has a peripheral fixation aid, and
it provides a numerical score. The score could be benefi-
cial in clinic and home monitoring of AMD progression,
as well as provide an outcome measure in clinical
research.
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First MMT scores taken from normal (over 50 years), ARM and AMD participants plotted against ageigure 7
First MMT scores taken from normal (over 50 years), ARM 
and AMD participants plotted against age.
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